KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Accounts Payables (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Accounts Payables for 16 consecutive years, with $2.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables rose 14.89% year-over-year to $2.5 billion, compared with a TTM value of $2.5 billion through Dec 2025, up 14.89%, and an annual FY2025 reading of $2.5 billion, up 14.89% over the prior year.
  • Accounts Payables was $2.5 billion for Q4 2025 at Teva Pharmaceutical Industries, up from $2.4 billion in the prior quarter.
  • Across five years, Accounts Payables topped out at $2.6 billion in Q4 2023 and bottomed at $1.5 billion in Q3 2021.
  • Average Accounts Payables over 5 years is $2.1 billion, with a median of $2.3 billion recorded in 2023.
  • The sharpest move saw Accounts Payables skyrocketed 39.45% in 2023, then fell 15.33% in 2024.
  • Year by year, Accounts Payables stood at $1.7 billion in 2021, then rose by 11.92% to $1.9 billion in 2022, then skyrocketed by 37.89% to $2.6 billion in 2023, then dropped by 15.33% to $2.2 billion in 2024, then increased by 14.89% to $2.5 billion in 2025.
  • Business Quant data shows Accounts Payables for TEVA at $2.5 billion in Q4 2025, $2.4 billion in Q3 2025, and $2.5 billion in Q2 2025.